168 related articles for article (PubMed ID: 25418492)
1. Role of RAAS and adipokines in cardiovascular protection: effect of different doses of angiotensin II receptor blocker on adipokines level in hypertensive patients.
Hass A; Oz H; Mashavi M; Shargorodsky M
J Am Soc Hypertens; 2014 Oct; 8(10):709-14. PubMed ID: 25418492
[TBL] [Abstract][Full Text] [Related]
2. High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering.
Shargorodsky M; Hass E; Boaz M; Gavish D; Zimlichman R
Atherosclerosis; 2008 Mar; 197(1):303-10. PubMed ID: 17588581
[TBL] [Abstract][Full Text] [Related]
3. Effect of angiotensin II receptor blockers, candesartan, on osteoprotegerin level in hypertensive patients: Link between bone and RAAS.
Oz H; Gavish D; Hass A; Shargorodsky M
J Renin Angiotensin Aldosterone Syst; 2015 Sep; 16(3):547-52. PubMed ID: 25694056
[TBL] [Abstract][Full Text] [Related]
4. Effects of angiotensin II type 1 receptor blocker and adiponectin on adipocyte dysfunction in stroke-prone spontaneously hypertensive rats.
Takemori K; Inoue T; Ito H
Lipids Health Dis; 2013 Jul; 12():108. PubMed ID: 23876211
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade.
de Vinuesa SG; Goicoechea M; Kanter J; Puerta M; Cachofeiro V; Lahera V; Gómez-Campderá F; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S206-12. PubMed ID: 17130263
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study.
Koyanagi R; Hagiwara N; Yamaguchi J; Kawada-Watanabe E; Haruta S; Takagi A; Ogawa H;
J Cardiol; 2013 Oct; 62(4):217-23. PubMed ID: 23778009
[TBL] [Abstract][Full Text] [Related]
7. Overweight, hypertension and cardiovascular disease: focus on adipocytokines, insulin, weight changes and natriuretic peptides.
Seven E
Dan Med J; 2015 Nov; 62(11):B5163. PubMed ID: 26522487
[TBL] [Abstract][Full Text] [Related]
8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
9. Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients.
Koh KK; Quon MJ; Lee Y; Han SH; Ahn JY; Chung WJ; Kim JA; Shin EK
Eur Heart J; 2007 Jun; 28(12):1440-7. PubMed ID: 17483542
[TBL] [Abstract][Full Text] [Related]
10. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
Papademetriou V; Farsang C; Elmfeldt D; Hofman A; Lithell H; Olofsson B; Skoog I; Trenkwalder P; Zanchetti A;
J Am Coll Cardiol; 2004 Sep; 44(6):1175-80. PubMed ID: 15364316
[TBL] [Abstract][Full Text] [Related]
11. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
Suzuki H; Kanno Y;
Hypertens Res; 2005 Apr; 28(4):307-14. PubMed ID: 16138560
[TBL] [Abstract][Full Text] [Related]
12. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Ogihara T; Fujimoto A; Nakao K; Saruta T;
Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.
Koh KK; Quon MJ; Han SH; Chung WJ; Lee Y; Shin EK
Int J Cardiol; 2006 Mar; 108(1):96-100. PubMed ID: 16246439
[TBL] [Abstract][Full Text] [Related]
14. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
Ovchinnikov AG; Serbul VM; Ageev FT
Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
[TBL] [Abstract][Full Text] [Related]
15. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension.
Furuhashi M; Ura N; Higashiura K; Murakami H; Tanaka M; Moniwa N; Yoshida D; Shimamoto K
Hypertension; 2003 Jul; 42(1):76-81. PubMed ID: 12796280
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin system blockade safely reduces blood pressure in patients with minor ischemic stroke during the acute phase.
Nakamura T; Tsutsumi Y; Shimizu Y; Uchiyama S
J Stroke Cerebrovasc Dis; 2010; 19(6):435-40. PubMed ID: 20702114
[TBL] [Abstract][Full Text] [Related]
18. Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients.
Furuya R; Odamaki M; Kumagai H; Hishida A
Blood Purif; 2006; 24(5-6):445-50. PubMed ID: 16940715
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.
Yamada S; Ano N; Toda K; Kitaoka A; Shiono K; Inoue G; Atsuda K; Irie J
Hypertens Res; 2008 Apr; 31(4):601-6. PubMed ID: 18633170
[TBL] [Abstract][Full Text] [Related]
20. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
Nakamura T; Kanno Y; Takenaka T; Suzuki H;
Hypertens Res; 2005 May; 28(5):415-23. PubMed ID: 16156505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
